Cargando…

Opioid Taper Practices Among Clinicians

INTRODUCTION: Opioid dose tapers are used frequently when cross-titrating from one or more opioids to another or when discontinuing therapy. Currently, there is no universally accepted evidence-based standard of care for this procedure which can leave patients at risk for withdrawal symptoms, inadeq...

Descripción completa

Detalles Bibliográficos
Autores principales: Persico, Amelia L, Bettinger, Jeffrey J, Wegrzyn, Erica L, Fudin, Jeffrey, Strassels, Scott A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542568/
https://www.ncbi.nlm.nih.gov/pubmed/34707403
http://dx.doi.org/10.2147/JPR.S322299
_version_ 1784589457843814400
author Persico, Amelia L
Bettinger, Jeffrey J
Wegrzyn, Erica L
Fudin, Jeffrey
Strassels, Scott A
author_facet Persico, Amelia L
Bettinger, Jeffrey J
Wegrzyn, Erica L
Fudin, Jeffrey
Strassels, Scott A
author_sort Persico, Amelia L
collection PubMed
description INTRODUCTION: Opioid dose tapers are used frequently when cross-titrating from one or more opioids to another or when discontinuing therapy. Currently, there is no universally accepted evidence-based standard of care for this procedure which can leave patients at risk for withdrawal symptoms, inadequate pain control, or elevated suicide risk. OBJECTIVE: The objective of this study was to examine practices and rationale among clinicians, to determine if there is a difference among respondents in their comfort level, method and rationale for tapering opioids at various morphine milligram equivalents (MME) and to assess the need for the development of a standard of care. METHODS: Data were derived from an electronic survey developed using SurveyMonkey(®). The survey was disseminated via e-mail listservs, social media, and professional organizations. Data were collected regarding profession, confidence tapering opioids at varying total MME, method and rationale for tapering, and pharmacologic management of withdrawal symptoms. Pearson’s Chi squared and Fisher’s exact tests were used to assess statistical significance of results. RESULTS: A total of 149 clinicians completed the survey, physicians, NPs, pharmacists, and PAs accounted for 51%, 20%, 19%, and 10% of participants, respectively. Overall, 55% of the respondents self-identified as pain specialists. There were no statistically significant differences in reported comfort level among the different types of providers. Nearly 50% of participants indicated their rationale for tapering or discontinuing opioids was the 2016 CDC guidelines. CONCLUSION: Despite that the majority of providers surveyed self-identified as pain specialists, over 50% were not comfortable tapering opioids at doses greater than 120 MME/day. This observation suggests a need for further education and establishment of consensus guidelines on method and rationale for opioid tapering. Provider motivation for tapering was largely influenced by CDC guidelines based on low quality evidence. This strengthens the argument for the creation of guidelines based on high quality evidence.
format Online
Article
Text
id pubmed-8542568
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85425682021-10-26 Opioid Taper Practices Among Clinicians Persico, Amelia L Bettinger, Jeffrey J Wegrzyn, Erica L Fudin, Jeffrey Strassels, Scott A J Pain Res Original Research INTRODUCTION: Opioid dose tapers are used frequently when cross-titrating from one or more opioids to another or when discontinuing therapy. Currently, there is no universally accepted evidence-based standard of care for this procedure which can leave patients at risk for withdrawal symptoms, inadequate pain control, or elevated suicide risk. OBJECTIVE: The objective of this study was to examine practices and rationale among clinicians, to determine if there is a difference among respondents in their comfort level, method and rationale for tapering opioids at various morphine milligram equivalents (MME) and to assess the need for the development of a standard of care. METHODS: Data were derived from an electronic survey developed using SurveyMonkey(®). The survey was disseminated via e-mail listservs, social media, and professional organizations. Data were collected regarding profession, confidence tapering opioids at varying total MME, method and rationale for tapering, and pharmacologic management of withdrawal symptoms. Pearson’s Chi squared and Fisher’s exact tests were used to assess statistical significance of results. RESULTS: A total of 149 clinicians completed the survey, physicians, NPs, pharmacists, and PAs accounted for 51%, 20%, 19%, and 10% of participants, respectively. Overall, 55% of the respondents self-identified as pain specialists. There were no statistically significant differences in reported comfort level among the different types of providers. Nearly 50% of participants indicated their rationale for tapering or discontinuing opioids was the 2016 CDC guidelines. CONCLUSION: Despite that the majority of providers surveyed self-identified as pain specialists, over 50% were not comfortable tapering opioids at doses greater than 120 MME/day. This observation suggests a need for further education and establishment of consensus guidelines on method and rationale for opioid tapering. Provider motivation for tapering was largely influenced by CDC guidelines based on low quality evidence. This strengthens the argument for the creation of guidelines based on high quality evidence. Dove 2021-10-20 /pmc/articles/PMC8542568/ /pubmed/34707403 http://dx.doi.org/10.2147/JPR.S322299 Text en © 2021 Persico et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Persico, Amelia L
Bettinger, Jeffrey J
Wegrzyn, Erica L
Fudin, Jeffrey
Strassels, Scott A
Opioid Taper Practices Among Clinicians
title Opioid Taper Practices Among Clinicians
title_full Opioid Taper Practices Among Clinicians
title_fullStr Opioid Taper Practices Among Clinicians
title_full_unstemmed Opioid Taper Practices Among Clinicians
title_short Opioid Taper Practices Among Clinicians
title_sort opioid taper practices among clinicians
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542568/
https://www.ncbi.nlm.nih.gov/pubmed/34707403
http://dx.doi.org/10.2147/JPR.S322299
work_keys_str_mv AT persicoamelial opioidtaperpracticesamongclinicians
AT bettingerjeffreyj opioidtaperpracticesamongclinicians
AT wegrzynerical opioidtaperpracticesamongclinicians
AT fudinjeffrey opioidtaperpracticesamongclinicians
AT strasselsscotta opioidtaperpracticesamongclinicians